1. Share Prices

  2. Hikma Pharmaceuticals PLC (HIK)

2,130.00p-12.00 (-0.56%)24 Jan 2025, 16:58
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Hikma Pharmaceuticals PLC Fundamentals

Company NameHikma Pharmaceuticals PLCLast Updated2025-01-24
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue221.885 mMarket Cap£4.74 bn
PE Ratio31.09Dividend per Share$0.62
Dividend Yield2.87Dividend Cover1.37
EPS$0.85EPS Growth (%)0.23
PEG0DPS Growth (%)0.1711
Debt Ratio0.2545Debt Equity Ratio0.4686
Asset Equity Ratio2.1186Cash Equity Ratio0.1037
Quick Ratio0.7603Current Ratio1.57
Price To Book Value2.6674ROCE0

Hikma Pharmaceuticals PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total
Interim2024-08-152024-09-20USD0.3200
Prelim2024-03-212024-05-03USD0.4700
Interim2023-08-102023-09-15GBP0.1988
Prelim2023-03-232023-05-05GBP0.2952
Interim2022-08-182022-09-20GBP0.1600
Prelim2022-03-172022-04-28GBP0.2600

Hikma Pharmaceuticals PLC Company Financials

Assets20232022
Tangible Assets$1.14 bn$1.08 bn
Intangible Assets$1.10 bn$1.12 bn
Investments$83.00 m$75.00 m
Total Fixed Assets$2.58 bn$2.47 bn
Stocks$891.00 m$776.00 m
Debtors$789.00 m$777.00 m
Cash & Equivalents$229.00 m$292.00 m
Other Assets$256.00 m$192.00 m
Total Assets$4.68 bn$4.47 bn
Liabilities20232022
Creditors within 1 year$1.34 bn$1.08 bn
Creditors after 1 year$1.13 bn$1.25 bn
Other Liabilities00
Total Liabilities$2.47 bn$2.32 bn
Net assets$2.21 bn$2.15 bn
Equity20232022
Called up share capital$40.00 m$40.00 m
Share Premium$282.00 m$282.00 m
Profit / Loss$281.00 m$233.00 m
Other Equity$2.20 bn$2.13 bn
Preference & Minorities$11.00 m$13.00 m
Total Capital Employed$2.21 bn$2.15 bn
Ratios20232022
Debt Ratio$0.32$0.35
Debt-to-Equity$0.47$0.53
Assets / Equity2.11862.1186
Cash / Equity0.10370.1037
EPS$1.70$1.39
Cash Flow20232022
Cash from operating activities$737.00 m$585.00 m
Cashflow before financing$400.00 m$527.00 m
Increase in Cash-$62.00 m-$135.00 m
Income20232022
Turnover$2.88 bn$2.52 bn
Cost of sales$1.49 bn$1.28 bn
Gross Profit$1.39 bn$1.24 bn
Operating Profit$367.00 m$282.00 m
Pre-Tax profit$281.00 m$233.00 m

Hikma Pharmaceuticals PLC Company Background

SectorHealthcare
ActivitiesHikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
Latest Interim Date8 Aug 2024
Latest Fiscal Year End Date22 Feb 2024

Hikma Pharmaceuticals PLC Directors

AppointedNamePosition
2023-03-16Dr. Pamela Josephine Kirby Non-Executive Director
2024-04-11Mr. Mazen Samih Taleb DarwazahExecutive Director,Vice Chairman
2014-05-15Sir David Kenneth Rowe-Ham GBENon-Executive Director
2017-05-19Mr. Michael Richard Dwyer AshtonNon-Executive Director
2014-05-15Mr. Samih DarwazahNon-Executive Director,Chairman
2024-03-22Mr. Mohammed Ali Khaldoun S Al-HusryNon-Executive Director
2016-05-12Mr. Breffni ByrneNon-Executive Director
2024-03-22Mr. Douglas Michael HurtNon-Executive Director
2018-05-18Dr. Ronald L GoodeNon-Executive Director
2024-06-05Mr. Said DarwazahExecutive Director,Chairman
2022-05-24Mr. Sigurdur O. OlafssonExecutive Director,Chief Executive Officer
2021-03-17Mr. Robert PickeringNon-Executive Director
2024-03-22Ms. Nina HendersonNon-Executive Director
2024-03-22Mr. Patrick ButlerNon-Executive Director
2024-03-22Mr. John Julius CastellaniNon-Executive Director
2024-03-22Ms. Cynthia L. FlowersNon-Executive Director
2024-03-22Dr. Deneen VojtaNon-Executive Director
2024-09-24Mr. Riad MishlawiExecutive Director,Chief Executive Officer

Hikma Pharmaceuticals PLC Contact Details

Company NameHikma Pharmaceuticals PLC
Address1 New Burlington Place, London, W1S 2HR
Telephone+44 2073992760
Websitehttps://www.hikma.com

Hikma Pharmaceuticals PLC Advisors

AuditorPricewaterhouseCoopers LLP
Phone+44 2075835000
Fax+44 2078224652
Remuneration ConsultantWillis Towers Watson
Phone+44 2071702000
Fax+44 2071702222
SolicitorSlaughter and May
Phone+44 2076001200
Fax+44 2070905000
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
StockbrokerBank of America Merrill Lynch
Phone+44 2076281000
Fax+44 2078672867
SolicitorAddleshaw Goddard LLP
Phone(020) 7606 8855
Fax(020) 7606 4390
Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
StockbrokerCiti
Phone+44 2079864000
Fax+44 2079862266

Most Read

Receive our
daily news email

Subscribe to the latest investing news by entering your email address below

You can opt out at any time.

For five days a week you will get

  • The latest company news
  • Insight into investment trends
  • Round-up of director's buys and sells
  • Articles from Shares magazine
Sharesmagazine cover

Plus more useful investment content and occasional promotional offers.

Shares Magazine Latest Issue Cover
Latest Issue:
23 Jan 2025Subscribe now

Market Overview

UK 350 Risers and Fallers

Risers

CompanyPrice% Chg
Burberry Group PLC1,173.509.62
Kainos Group PLC798.004.18
Diageo PLC2,501.504.16
Bloomsbury Publishing PLC680.003.98
Babcock International Group PLC519.003.59
Pets AT Home Group PLC210.803.23

Fallers

CompanyPrice% Chg
Harbour Energy PLC255.80-7.12
Energean PLC964.50-4.98
Diversified Energy Company PLC1,264.00-4.10
Ocado Group PLC300.90-3.90
Marks And Spencer Group PLC320.00-3.85
Pennon Group PLC499.70-3.25